Guiding pluripotent stem cell therapies past the immune system.
Guiding pluripotent stem cell therapies past the immune system.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Tucson, US · Author affiliation
Center for Advanced Molecular and Immunological Therapies, University of Arizona, Tucson, AZ 85724, United States.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
Pluripotent stem cell (PSC)-based therapies hold the potential to unlock cures for numerous diseases, including, but not limited to, Parkinson's disease, macular degeneration, heart failure, type 1 diabetes, and cancer. Yet as protocols to differentiate PSCs into therapeutically useful cell types have progressed rapidly, immunological rejection remains a major barrier that may limit the widespread use of such PSC-based therapies. In recent years, strategies to genetically modify PSCs to prevent immunological rejection of the downstream cell product have become a point of emphasis. Here, we provide an immunological perspective on these strategies, discussing the breadth of rejection mechanisms that have been uncovered through decades of research and the relative simplicity of designing PSC immune evasion strategies to circumvent these mechanisms. We focus in particular on how these strategies apply to the treatment of type 1 diabetes.